Facilitation of male sexual behavior in adult male rats by the aromatization inhibitor, 1,4,6-androstatriene-3,17-dione (ATD)

Effects of ATD on male sexual behavior and androgen receptor binding: a reexamination of the aromatization hypothesis

The aromatization hypothesis asserts that testosterone (T) must be aromatized to estradiol (E2) to activate copulatory behavior in the male rat. In support of this hypothesis, the aromatization inhibitor, ATD, has been found to suppress male sexual behavior in T-treated rats. In our experiment, we first replicated this finding by peripherally injecting ATD (15 mg/day) or propylene glycol into T-treated (two 10-mm Silastic capsules) or control castrated male rats. In a second experiment, we bilaterally implanted either ATD-filled or blank cannulae into the medial preoptic area (MPOA) of either T-treated or control castrated male rats. With this more local distribution of ATD, a lesser decline in sexual behavior was found, suggesting that other brain areas are involved in the neurohormonal activation of copulatory behavior in the male rat. To determine whether in vivo ATD interacts with androgen or estrogen receptors, we conducted cell nuclear androgen and estrogen receptor binding assays of hypothalamus, preoptic area, amygdala, and septum following treatment with the combinations of systemic T alone. ATD plus T, ATD alone, and blank control. In all four brain areas binding of T to androgen receptors was significantly decreased in the presence of ATD, suggesting that ATD may act both as an androgen receptor blocker and as an aromatization inhibitor. Competitive binding studies indicated that ATD competes in vitro for cytosol androgen receptors, thus substantiating the in vivo antiandrogenic effects of ATD. Cell nuclear estrogen receptor binding was not significantly increased by exposure to T in the physiological range. No agonistic properties of ATD were observed either behaviorally or biochemically. Thus, an alternative explanation for the inhibitory effects of ATD on male sexual behavior is that ATD prevents T from binding to androgen receptors.

Evidence implicating aromatization of testosterone in the regulation of male ferret sexual behavior

We compared the effects of the aromatase inhibitor, 1,4,6-androstatriene-3,17-dione (ATD) and castration on the expression of mating behavior in adult male ferrets which were in breeding condition. Males implanted SC with Silastic capsules containing ATD displayed significantly less neck gripping, mounting and intromittive behavior than intact males which received empty capsules, although the ATD-induced reductions in behavior were not as large as those seen after castration. ATD had no effect on mating behavior in castrated males. As reported in another publication, brain aromatase activity was significantly reduced in both the intact and castrated males treated with ATD in the present study. Plasma estradiol (E2) levels were uniformly low in intact and castrated males, regardless of whether they received ATD or no steroid. As expected, plasma testosterone (T) levels were significantly lower in castrated than in intact males, and ATD treatment did not affect these values. These results suggest that E2 formed via the neural aromatization of T contributes to the activation of masculine sexual behavior in intact male ferrets in breeding condition.

Effects of metabolism inhibitors, antiestrogens and antiandrogens on the androgen and estrogen induced sexual behavior in Japanese quail

The relative contribution of androgenic and estrogenic metabolites of testosterone to the activation of sexual behavior was studied in Japanese quail by using inhibitors of testosterone metabolism, antiestrogens and antiandrogens. These compounds were tested in castrated birds whose sexual behavior had been activated by silastic implants of testosterone (T) or daily injections of testosterone propionate (TP) or diethylstilboestrol (DES). The aromatase inhibitor ATD only depressed T-induced behavior when injected at high doses and the 5 alpha-reductase inhibitor, 4MA was inactive in this respect. The antiestrogens, tamoxifen (TAM) and nitromifene citrate (CI-628) strongly depressed sexual behavior but they also drastically reduced the crowing behavior which is typically androgen-dependent which throws some doubts on the specificity of their action. The antiandrogens, flutamide and cyproterone acetate (CA), only had limited inhibitory effects on the copulatory behavior but similarly decreased only marginally the crowing. As they strongly depressed the cloacal gland growth, it can be ascertained that they were injected in sufficient amounts and their lack of action on crowing questions the ability of these compounds to inhibit brain processes even when they are androgen-dependent. Taken together with the results of previous experiments which tested the behavioral effects of the testosterone metabolites, the present data confirm the implication of both androgenic and estrogenic metabolites of testosterone in the activation of behavior. Their interaction remains, however, poorly defined and its understanding will probably require the identification of the biochemical processes which in the brain mediate the behavior.

Perinatal androgen manipulations do not affect feminine behavioral potentials in voles

Adult voles show sexual differences in their behavioral responses to estrogen. To determine whether this sexual dimorphism is related to early androgen exposure as it is in other rodents, female voles were treated neonatally with testosterone. In addition, males were castrated neonatally or treated perinatally with either the antiandrogen, flutamide or with the antiaromatase, ATD. When androgenized females were treated with estrogen in adulthood, they exhibited normal sexual behaviors. Males deprived of androgen or treated with ATD during development did not display feminine behaviors when injected with estrogen in adulthood. These results suggest that the organizational hypothesis of sexual differentiation cannot explain the development of feminine behavior potentials in the vole. It is possible that the development of feminine behaviors in voles requires exposure to ovarian hormones during prepubertal development.

Organization and activation of behavior in quail: role of testosterone metabolism

In quail, the hypothalamus enzymatically transforms testosterone (T) into estradiol (E2), 5 alpha-dihydrotestosterone (5 alpha-DHT), and 5 beta-dihydrotestosterone (5 beta-DHT). During the embryonic life, the 5 beta-reductase activity is very high, which probably protects the brain of males from being behaviorally demasculinized by their endogenous T. 5 beta androstanes are inactive androgens. The decrease of 5 beta reductase with age during sexual maturation corresponds to a potentiation of the effects of T as shown by experiments that compared the effects of T and 5 alpha-DHT in adult and young quail. T metabolism is also involved in the activation of male behavior in the adult. T aromatization is probably essential for behavioral activation, but nonaromatizable androgens such as methyltrienolone, and to some extent 5 alpha-DHT, can also stimulate sexual behavior in castrates. These enzymatic activities show a clear neuroanatomical localization and are sexually dimorphic. Males produce more active metabolites (E2, 5 alpha-DHT) than females, which could explain the male's greater sensitivity to T treatments. It thus appears that T metabolism is involved in the differentiation and activation of behavior in quail.

Multiple actions of steroids and their antagonists

Our scientific language is often misleading. We speak, for example, of virilizing progestins when we should be speaking of "dihydrotestosterone-like" progestins because genital virilization is normally brought about by DHT. We speak of the anti-libidinal properties of antiandrogens as though we knew that their mechanism of action was through the blockage of androgen receptors; some of these agents are antiestrogenic and progestational as well. Until we know the mechanism of action of androgens, estrogens, antiandrogens, antiestrogens, aromatase inhibitors, and reductase inhibitors we should be cautious in our terminology. All hormones and their antagonists have multiple effects.